Rti Surgical, Inc
$1.4M 821 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Esteve Pharmaceuticals LLC
Esteve Pharmaceuticals LLC reported $1,431,875.93 across General Payments, Research, and Ownership to 8 physicians and teaching hospitals across 12 transactions.
- $1.4M Above-median payer
- All-tracks total
- 12 Below-median volume
- Transactions
- 8 Below-median reach
- Recipients
- #535
- of 1,925 companies
Esteve Pharmaceuticals LLC reported $1,431,875.93 across all CMS Open Payments tracks (General + Research + Ownership) to 8 physicians and teaching hospitals in Program Year 2024 - ranking #535 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $93,458.93, averaging $179.0K per recipient.
How Esteve Pharmaceuticals LLC's $1.4M all-tracks total breaks down
Esteve Pharmaceuticals LLC's payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
33/100
Total payments
F
23/100
Transaction volume
F
10/100
Physician reach
F
10/100
Payment type diversity
A
90/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer esteve-pharmaceuticals-llc Esteve Pharmaceuticals LLC
$1.4M · #535/1,925 · 0.0% industry · PY2024
- TOT $1.4M
- RANK #535
- SHARE 0.0%
- TXN 12
- RCP 8
- CAT 7
- GEN $93.5K
- TOP1 80.2%
- PY 2024
Volume peers
Nearest volume peer: Rti Surgical, Inc ($1.4M)
Esteve Pharmaceuticals LLC sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
What the Data Shows for Esteve Pharmaceuticals LLC
CMS Open Payments is not a single ledger: the all-tracks total shown above is General Payments plus Research Payments plus Ownership/Investment interests, each with its own disclosure rules. For Esteve Pharmaceuticals LLC, that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. Data for a given Program Year arrives roughly a year after the period it covers; our methodology page documents the release cadence and how we standardize the tracks for cross-company comparison.
"Space Rental or Facility Fees" leads the 7-category general-payment breakdown below at $75.0K (80.2% of General Payments, 1 transactions) - see our methodology for how research and ownership payments are reported separately.
General Payment Breakdown by Type
Across 7 types of general payments, Esteve Pharmaceuticals LLC's largest category was "Space Rental or Facility Fees" at $75.0K - 80.2% of General Payments.
Esteve Pharmaceuticals LLC reports 7 general-payment categories - the top three are Space Rental or Facility Fees (80.2%), Travel and Lodging (12.1%), and Consulting Fee (2.4%). The remaining 4 categories make up 5.2% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How Esteve Pharmaceuticals LLC divides its payments
How the reported total splits across payment categories
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Space Rental or Facility Fees | $75.0K | 1 | 80.2% |
| Travel and Lodging | $11.3K | 2 | 12.1% |
| Consulting Fee | $2.3K | 1 | 2.4% |
| Honoraria | $1.9K | 1 | 2.1% |
| Grant | $1.9K | 1 | 2.1% |
| Education | $979.85 | 1 | 1.0% |
| Food and Beverage | $91.65 | 1 | 0.1% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $93,458.93 (100.0%) of $93,458.93 in this company's General Payments records across 4 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Esteve Pharmaceuticals LLC
The five named recipients with the highest reported General Payments from this company
- 1
Ut Md Anderson Cancer Center
$75,000.00 across 1 reported transactions
- 2
Irina Bancos
$8,785.25 across 2 reported transactions
- 3
Eliza Geer
$7,423.68 across 4 reported transactions
- 4
Ankur Mehta
$2,250.00 across 1 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Esteve Pharmaceuticals LLC's spend rank (#535 of 1,925, top 28% by spend) and concentration rank (#240 of 1,838, top 13% most concentrated) land at roughly the same percentile, an unusually proportionate case where payment size and payment concentration move together.
View all 12 companies in this HHI neighborhood as a list
- Vy Spine LLC : $143.43 total payments, HHI 6811
- IZI Medical Products, LLC : $59.6K total payments, HHI 6805
- Lexington Medical, Inc. : $67.4K total payments, HHI 6779
- Milestone Scientific Inc. : $1.3M total payments, HHI 6693
- Volpara Health, Inc : $152.0K total payments, HHI 6645
- Epien Medical, Inc. : $7.0K total payments, HHI 6624
- Esteve Pharmaceuticals LLC (this company) : $93.5K total payments, HHI 6597
- Philadelphia Medical Management Company LLC : $174.9K total payments, HHI 6579
- Bernhard Foerster GmbH : $347.7K total payments, HHI 6541
- Helios Cardio Inc : $17.4K total payments, HHI 6534
- Instrumentation Laboratory Company : $1.4M total payments, HHI 6528
- KARL STORZ SE & Co. KG : $39.6K total payments, HHI 6505
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Esteve Pharmaceuticals LLC's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Esteve Pharmaceuticals LLC.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Esteve Pharmaceuticals LLC.
Showing 6 of 1,924 companies with CMS-reported payment data.
Aurora Spine, Inc.
$1.4M 186 recipients
Compare payment profiles
Tactile Systems Technology Inc
$1.4M 10,628 recipients
Compare payment profiles
ANI Pharmaceuticals, Inc.
$1.5M 21,104 recipients
Compare payment profiles
Seres Therapeutics, Inc.
$1.5M 42 recipients
Compare payment profiles
BioHorizons Implant Systems Inc.
$1.4M 9,712 recipients
Compare payment profiles
Put this to use
Esteve Pharmaceuticals LLC ranks #535 of 1,925 by all-tracks total payments, led by "Space Rental or Facility Fees".
- See where Esteve Pharmaceuticals LLC sits among every top spender on the full leaderboard. Top 100 by total payments
- Compare "Space Rental or Facility Fees" spend across every manufacturer, not just Esteve Pharmaceuticals LLC. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.